{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:34:07Z","timestamp":1790836447584,"version":"4.1.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.lpm.2022.104158","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T20:25:41Z","timestamp":1671654341000},"page":"104158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Clinical pharmacology of antidiabetic drugs: What can be expected of their use?"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9743-4371","authenticated-orcid":false,"given":"Andr\u00e9 J.","family":"Scheen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2022.104158_bib0001","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(20)32374-6","article-title":"The Lancet Commission on diabetes: using data to transform diabetes care and patient lives","volume":"396","author":"Chan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2022.104158_bib0002","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting lecture. from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.lpm.2022.104158_bib0003","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2022.104158_bib0004","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.lpm.2022.104158_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.deman.2021.100005","article-title":"Exciting breakthroughs in the management of diabetes mellitus","volume":"1","author":"Scheen","year":"2021","journal-title":"Diabetes Epidemiol Manag"},{"key":"10.1016\/j.lpm.2022.104158_bib0006","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003495-199855020-00004","article-title":"Oral antidiabetic agents. A guide to selection","volume":"55","author":"Scheen","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.lpm.2022.104158_bib0007","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2022.104158_bib0008","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.lpm.2022.104158_bib0009","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41574-020-0392-2","article-title":"Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus","volume":"16","author":"Scheen","year":"2020","journal-title":"Nature Rev Endocrinol"},{"key":"10.1016\/j.lpm.2022.104158_bib0010","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.amjcard.2017.05.009","article-title":"Pharmacologic management of type 2 diabetes mellitus: available therapies","volume":"120","author":"Thrasher","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.lpm.2022.104158_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155332","article-title":"Pharmacotherapy of type 2 diabetes: an update and future directions","volume":"137","author":"DeMarsilis","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.lpm.2022.104158_bib0012","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.2337\/dc22-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lpm.2022.104158_bib0013","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(08)61207-6","article-title":"Exenatide once weekly in type 2 diabetes","volume":"372","author":"Scheen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2022.104158_bib0014","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: historical overview","volume":"60","author":"Bailey","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.lpm.2022.104158_bib0015","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2022.104158_bib0016","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.diabet.2013.02.006","article-title":"Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes","volume":"39","author":"Scheen","year":"2013","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0017","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.2337\/dc10-2361","article-title":"Use of metformin in the setting of mild-to-moderate renal insufficiency","volume":"34","author":"Lipska","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lpm.2022.104158_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.944902","article-title":"Effect of metformin on adverse outcomes in T2DM patients: systemic review and meta-analysis of observational studies","volume":"9","author":"Xu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.lpm.2022.104158_bib0019","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.2337\/dc16-2372","article-title":"Is it time to change the type 2 diabetes treatment paradigm? No! Metformin should remain the foundation therapy for type 2 diabetes","volume":"40","author":"Inzucchi","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lpm.2022.104158_bib0020","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2337\/dc16-2368","article-title":"Is it time to change the type 2 diabetes treatment paradigm? Yes! GLP-1 RAs should replace metformin in the type 2 diabetes algorithm","volume":"40","author":"Abdul-Ghani","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lpm.2022.104158_bib0021","doi-asserted-by":"crossref","DOI":"10.1177\/2042018820980225","article-title":"Should metformin remain the first-line therapy for treatment of type 2 diabetes?","volume":"12","author":"Baker","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0022","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.diabet.2019.10.006","article-title":"Challenging 2019 ESC guidelines for the management of type 2 diabetes","volume":"46","author":"Scheen","year":"2020","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107946","article-title":"The right place for metformin today","volume":"159","author":"Schernthaner","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.lpm.2022.104158_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155160","article-title":"Metformin and the heart: update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure","volume":"130","author":"Schernthaner","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.lpm.2022.104158_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155223","article-title":"Metformin: is it a drug for all reasons and diseases?","volume":"133","author":"Triggle","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.lpm.2022.104158_bib0026","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12902-022-01158-5","article-title":"Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs","volume":"22","author":"Volke","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.lpm.2022.104158_bib0027","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.diabet.2018.05.007","article-title":"Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: results of randomized controlled trials and observational studies","volume":"44","author":"Scheen","year":"2018","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0028","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S2213-8587(18)30025-1","article-title":"Do sulphonylureas still have a place in clinical practice?","volume":"6","author":"Khunti","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.lpm.2022.104158_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.deman.2021.100002","article-title":"Sulphonylureas in the management of type 2 diabetes: to be or not to be ?","volume":"1","author":"Scheen","year":"2021","journal-title":"Diabetes Epidemiol Manag"},{"key":"10.1016\/j.lpm.2022.104158_bib0030","first-page":"781","article-title":"Prise de position de la Soci\u00e9t\u00e9 Francophone du Diab\u00e8te (SFD) sur les strat\u00e9gies d'utilisation des traitements anti-hyperglyc\u00e9miants dans le diab\u00e8te de type 2 - 2021","volume":"15","author":"Darmon","year":"2021","journal-title":"Med Mal Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0031","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2337\/dc14-0565","article-title":"Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on!","volume":"38","author":"Genuth","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lpm.2022.104158_bib0032","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2337\/dc14-1945","article-title":"Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? Yes, they continue to serve us well!","volume":"38","author":"Abrahamson","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lpm.2022.104158_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107836","article-title":"The right place for sulphonylureas today","volume":"157","author":"Webb","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.lpm.2022.104158_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13300-019-0573-y","article-title":"The standard of care in type 2 diabetes: re-evaluating the treatment paradigm","volume":"10","author":"Mohan","year":"2019","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.lpm.2022.104158_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2018.05.028","article-title":"The place of gliclazide MR in the evolving type 2 diabetes landscape: a comparison with other sulfonylureas and newer oral antihyperglycemic agents","volume":"143","author":"Colagiuri","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.lpm.2022.104158_bib0036","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13300-020-00833-x","article-title":"Role of gliclazide MR in the management of type 2 diabetes: report of a symposium on real-world evidence and new perspectives","volume":"11","author":"Khunti","year":"2020","journal-title":"Diabetes Ther"},{"issue":"Suppl 2","key":"10.1016\/j.lpm.2022.104158_bib0037","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13968","article-title":"ADVANCE in context: the benefits, risks and feasibility of providing intensive glycaemic control based on gliclazide modified release","volume":"22","author":"Zoungas","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0038","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/jama.2019.14533","article-title":"Sulfonylureas and cardiovascular safety: the final verdict?","volume":"322","author":"Wexler","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2022.104158_bib0039","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S2213-8587(17)30317-0","article-title":"Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial","volume":"5","author":"Vaccaro","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.lpm.2022.104158_bib0040","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-Jarvinen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2022.104158_bib0041","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/ncpendmet0781","article-title":"Do thiazolidinediones increase the risk of congestive heart failure and cardiovascular death?","volume":"4","author":"Scheen","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0042","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2022.104158_bib0043","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2022.104158_bib0044","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.diabres.2012.09.001","article-title":"Outcomes and lessons from the PROactive study","volume":"98","author":"Scheen","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.lpm.2022.104158_bib0045","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2022.104158_bib0046","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/dom.14687","article-title":"Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance","volume":"24","author":"Spence","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0047","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2165\/00002018-200124120-00002","article-title":"Hepatotoxicity with thiazolidinediones: is it a class effect?","volume":"24","author":"Scheen","year":"2001","journal-title":"Drug Saf"},{"key":"10.1016\/j.lpm.2022.104158_bib0048","first-page":"e25380","article-title":"The Role of thiazolidinediones in the amelioration of nonalcoholic fatty liver disease: a systematic review","volume":"14","author":"Ndakotsu","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.lpm.2022.104158_bib0049","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/dom.12101","article-title":"Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?","volume":"15","author":"Consoli","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0050","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1479164118825376","article-title":"Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes","volume":"16","author":"DeFronzo","year":"2019","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.lpm.2022.104158_bib0051","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/dom.12652","article-title":"Revitalization of pioglitazone: the optimal agent to be combined with an SGLT2 inhibitor","volume":"18","author":"DeFronzo","year":"2016","journal-title":"Diabetes Obesity Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0052","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11892-019-1270-y","article-title":"Thiazolidinediones: the forgotten diabetes medications","volume":"19","author":"Lebovitz","year":"2019","journal-title":"Curr Diabetes Rep"},{"key":"10.1016\/j.lpm.2022.104158_bib0053","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14656566.2020.1853100","article-title":"Are thiazolidinediones a preferred drug treatment for type 2 diabetes?","volume":"22","author":"Hurren","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.lpm.2022.104158_bib0054","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2337\/diacare.28.1.154","article-title":"Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis","volume":"28","author":"van de Laar","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lpm.2022.104158_bib0055","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/jdi.12711","article-title":"Meta-analysis and critical review on the efficacy and safety of alpha-glucosidase inhibitors in Asian and non-Asian populations","volume":"9","author":"Gao","year":"2018","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.lpm.2022.104158_bib0056","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3389\/fendo.2020.00288","article-title":"Acarbose with comparable glucose-lowering but superior weight-loss efficacy to dipeptidyl peptidase-4 inhibitors: a systematic review and network meta-analysis of randomized controlled trials","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.lpm.2022.104158_bib0057","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12933-019-0933-y","article-title":"Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes","volume":"18","author":"Coleman","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.lpm.2022.104158_bib0058","article-title":"Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus","volume":"12","author":"Moelands","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.lpm.2022.104158_bib0059","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2165\/00003495-200363100-00002","article-title":"Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?","volume":"63","author":"Scheen","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.lpm.2022.104158_bib0060","doi-asserted-by":"crossref","first-page":"e14497","DOI":"10.1111\/dme.14497","article-title":"Pharmacological management of South Asians with type 2 diabetes: consensus recommendations from the South Asian Health Foundation","volume":"38","author":"Hanif","year":"2021","journal-title":"Diabet Med"},{"key":"10.1016\/j.lpm.2022.104158_bib0061","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1080\/14656566.2019.1672660","article-title":"Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes","volume":"20","author":"Hedrington","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.lpm.2022.104158_bib0062","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.diabet.2011.11.001","article-title":"DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials","volume":"38","author":"Scheen","year":"2012","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0063","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejim.2011.10.007","article-title":"Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes","volume":"23","author":"Scheen","year":"2012","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.lpm.2022.104158_bib0064","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ando.2012.06.002","article-title":"GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician?","volume":"74","author":"Scheen","year":"2013","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.lpm.2022.104158_bib0065","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.diabet.2020.01.002","article-title":"Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: a systematic review of randomized controlled trials","volume":"46","author":"Scheen","year":"2020","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0066","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14740338.2018.1444027","article-title":"The safety of gliptins: updated data in 2018","volume":"17","author":"Scheen","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.lpm.2022.104158_bib0067","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1080\/14656566.2021.1912735","article-title":"Careful use to minimize adverse events of oral antidiabetic medications in the elderly","volume":"22","author":"Scheen","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.lpm.2022.104158_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2021.101275","article-title":"Efficacy \/safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes","volume":"47","author":"Scheen","year":"2021","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0069","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4330\/wjc.v13.i10.585","article-title":"Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of cardiovascular outcome trials","volume":"13","author":"Patoulias","year":"2021","journal-title":"World J Cardiol"},{"key":"10.1016\/j.lpm.2022.104158_bib0070","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrcardio.2012.183","article-title":"Cardiovascular effects of gliptins","volume":"10","author":"Scheen","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.lpm.2022.104158_bib0071","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3810\/pgm.2013.05.2659","article-title":"Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes","volume":"125","author":"Scheen","year":"2013","journal-title":"Postgrad Med"},{"key":"10.1016\/j.lpm.2022.104158_bib0072","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/CIRCRESAHA.114.301958","article-title":"Cardiovascular actions of incretin-based therapies","volume":"114","author":"Ussher","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.lpm.2022.104158_bib0073","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12933-022-01474-z","article-title":"The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs","volume":"21","author":"Giugliano","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.lpm.2022.104158_bib0074","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/CIRCRESAHA.117.311588","article-title":"Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors","volume":"122","author":"Scheen","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.lpm.2022.104158_bib0075","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1463-1326.2010.01212.x","article-title":"Pharmacokinetics of dipeptidylpeptidase-4 inhibitors","volume":"12","author":"Scheen","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0076","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(19)32131-2","article-title":"Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial","volume":"394","author":"Matthews","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2022.104158_bib0077","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12933-021-01430-3","article-title":"SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.lpm.2022.104158_bib0078","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.diabres.2018.06.008","article-title":"Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists","volume":"143","author":"Scheen","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.lpm.2022.104158_bib0079","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12933-021-01400-9","article-title":"GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.lpm.2022.104158_bib0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-060655","article-title":"Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials","volume":"12","author":"Tsai","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.lpm.2022.104158_bib0081","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.lpm.2022.104158_bib0082","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2022.104158_bib0083","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.lpm.2022.104158_bib0084","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.3390\/ijms23073651","article-title":"An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors","volume":"23","author":"Salvatore","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.lpm.2022.104158_bib0085","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nature Rev Nephrol"},{"key":"10.1016\/j.lpm.2022.104158_bib0086","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/17446651.2022.2014322","article-title":"Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease","volume":"17","author":"Scheen","year":"2022","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0087","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","article-title":"Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: potential contribution for diabetic complications and cardiovascular disease","volume":"44","author":"Bonnet","year":"2018","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0088","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diabet.2019.01.008","article-title":"Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications","volume":"45","author":"Scheen","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0089","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.747620","article-title":"Sodium-glucose ootransporter 2 (SGLT2) inhibitors vs. dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset dementia: a propensity score-matched population-based study with competing risk analysis","volume":"8","author":"Mui","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.lpm.2022.104158_bib0090","doi-asserted-by":"crossref","DOI":"10.1177\/14791641221098168","article-title":"The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: a nationwide population-based longitudinal cohort study","volume":"19","author":"Siao","year":"2022","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.lpm.2022.104158_bib0091","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14740338.2019.1602116","article-title":"An update on the safety of SGLT2 inhibitors","volume":"18","author":"Scheen","year":"2019","journal-title":"Expert Opin Drug Safety"},{"key":"10.1016\/j.lpm.2022.104158_bib0092","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2021.101315","article-title":"Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: a comprehensive review with a special reference to RAAS blockers","volume":"48","author":"Scheen","year":"2022","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0093","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"Frias","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.lpm.2022.104158_bib0094","article-title":"The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.lpm.2022.104158_bib0095","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s13300-018-0420-6","article-title":"Combination treatment of SGLT2 inhibitors and GLP-1 receptor agonists: symbiotic effects on metabolism and cardiorenal risk","volume":"9","author":"Goncalves","year":"2018","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.lpm.2022.104158_bib0096","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.lpm.2022.104158_bib0097","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0098","first-page":"168","article-title":"Insulin vs GLP-1 analogues in poorly controlled Type 2 diabetic subjects on oral therapy: a meta-analysis","volume":"36","author":"Abdul-Ghani","year":"2013","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.lpm.2022.104158_bib0099","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.lpm.2022.104158_bib0100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/bs.apha.2022.02.005","article-title":"Cardiovascular effects of GLP-1 receptor agonism","volume":"94","author":"Winquist","year":"2022","journal-title":"Adv Pharmacol"},{"issue":"Suppl 3","key":"10.1016\/j.lpm.2022.104158_bib0101","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0102","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.lpm.2022.104158_bib0103","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.lpm.2022.104158_bib0104","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.diabet.2017.12.009","article-title":"GLP-1 receptor agonists and cardiovascular protection. Class effect or not ?","volume":"44","author":"Scheen","year":"2018","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0105","article-title":"Dual GIP\/GLP-1 receptor agonists: new advance for treating type 2 diabetes","author":"Scheen","year":"2022","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.lpm.2022.104158_bib0106","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14831","article-title":"Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective","volume":"25","author":"De Block","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0107","doi-asserted-by":"crossref","first-page":"389","DOI":"10.7326\/0003-4819-130-5-199903020-00002","article-title":"Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial","volume":"130","author":"Yki-Jarvinen","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2022.104158_bib0108","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s13300-022-01286-0","article-title":"Practical guidance on basal insulin initiation and titration in Asia: a delphi-based consensus","volume":"13","author":"Chan","year":"2022","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.lpm.2022.104158_bib0109","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12902-016-0120-z","article-title":"Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials","volume":"16","author":"Erpeldinger","year":"2016","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.lpm.2022.104158_bib0110","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.numecd.2022.03.007","article-title":"Effects of insulin on cardiovascular events and all-cause mortality in patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"32","author":"Mannucci","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.lpm.2022.104158_bib0111","doi-asserted-by":"crossref","first-page":"bvaa193","DOI":"10.1210\/jendso\/bvaa193","article-title":"The association between baseline insulin treatment and cardiovascular events: a meta-analysis","volume":"5","author":"Khatib","year":"2021","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.lpm.2022.104158_bib0112","doi-asserted-by":"crossref","DOI":"10.1177\/14791641221093175","article-title":"Impact of insulin therapy on outcomes of diabetic patients with heart failure: a systematic review and meta-analysis","volume":"19","author":"Liu","year":"2022","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.lpm.2022.104158_bib0113","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2022.104158_bib0114","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1615692","article-title":"Efficacy and safety of degludec versus glargine in type 2 diabetes","volume":"377","author":"Marso","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2022.104158_bib0115","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/S0140-6736(14)61335-0","article-title":"Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis","volume":"384","author":"Eng","year":"2014","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.lpm.2022.104158_bib0116","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/dom.14552","article-title":"The ongoing evolution of basal insulin therapy over 100 years and its promise for the future","volume":"24","author":"Retnakaran","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.lpm.2022.104158_bib0117","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102615","article-title":"Once-weekly basal insulin icodec: looking ONWARDS from pharmacology to clinical trials","volume":"16","author":"Singh","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.lpm.2022.104158_bib0118","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.diabres.2016.04.033","article-title":"Precision medicine: the future in diabetes care?","volume":"117","author":"Scheen","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.lpm.2022.104158_bib0119","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s00125-022-05782-7","article-title":"Diabetes precision medicine: plenty of potential, pitfalls and perils but not yet ready for prime time","volume":"65","author":"Griffin","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.lpm.2022.104158_bib0120","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.807548","article-title":"Trends in antidiabetic drug discovery: FDA approved drugs, new drugs in clinical trials and global sales","volume":"12","author":"Dahl\u00e9n","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498222000513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498222000513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:09:41Z","timestamp":1760105381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498222000513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":120,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0755498222000513"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2022.104158","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical pharmacology of antidiabetic drugs: What can be expected of their use?","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2022.104158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104158"}}